Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial

rVSVΔG-ZEBOV-GP is the first approved vaccine with clinical efficacy against Ebola virus disease. Although a seroprotective threshold has not been defined for those at occupational risk of exposure, the current vaccine strategy is to attain a sustained high level of antibody titres. The aim of this...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet. Microbe 2024-11, Vol.5 (11), p.100923, Article 100923
Hauptverfasser:	Davey, Richard T, Collins, Gary L, Rouphael, Nadine, Poliquin, Guillaume, McConnell, Rosemary, Grubbs, Gabrielle, Moir, Susan L, Langley, Joanne M, Teitelbaum, Marc, Hewlett, Angela L, McLellan, Susan L F, Bhadelia, Nahid, Raabe, Vanessa N, Mulligan, Mark J, Maljkovic Berry, Irina, Dighero-Kemp, Bonnie, Kurtz, Jonathan R, Hensley, Lisa E, Dozier, Nelson C E, Marron, Lindsay C B, DuChene, Alain, Kuhn, Jens H, Brown, Shawn K, Khurana, Surender, Lane, H Clifford, Neaton, James D
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Viral - blood Canada Ebola Vaccines - administration & dosage Ebola Vaccines - adverse effects Ebola Vaccines - immunology Ebolavirus - immunology Female Hemorrhagic Fever, Ebola - immunology Hemorrhagic Fever, Ebola - prevention & control Humans Immunization, Secondary - methods Immunogenicity, Vaccine Male Middle Aged United States Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!